These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28169017)

  • 1. Re: Alessandro Morlacco, John C. Cheville, Laureano J. Rangel, Derek J. Gearman, R. Jeffrey Karnes. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-risk" Prostate Cancer: Implications for Active Surveillance. Eur Urol 2017;72:442-7.
    Du C; Chen H; Li C
    Eur Urol; 2017 Nov; 72(5):e125. PubMed ID: 28169017
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Thomas Van den Broeck, R. Jeffrey Karnes, and Steven Joniau's Letter to the Editor re: Amar U. Kishan, Talha Shaikh, Pin-Chieh Wang, et al. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol 2017;71:766-73.
    Kishan AU; Steinberg ML; Kupelian PA; King CR
    Eur Urol; 2017 Nov; 72(5):e123-e124. PubMed ID: 28111115
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Alberto Martini, Giorgio Gandaglia, R. Jeffrey Karnes, et al. Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer. Eur Urol Oncol 2019;2:456-63.
    Giannarini G; Crestani A; Ficarra V
    Eur Urol Oncol; 2019 Jul; 2(4):472-473. PubMed ID: 31277786
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Radiation therapy after radical prostatectomy: impact on metastasis and survival S. A. Boorjian, R. J. Karnes, P. L. Crispen, L. J. Rangel, E. J. Bergstralh and M. L. Blute J Urol 2009; 182: 2708-2715.
    Trock BJ; Walsh PC
    J Urol; 2010 Jun; 183(6):2466-7; author reply 2467. PubMed ID: 20403615
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036.
    Ayubi E; Safiri S
    Eur Urol; 2017 Dec; 72(6):e157. PubMed ID: 28576506
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to Pim J. van Leeuwen and Henk G. van der Poel's Letter to the Editor re: Karim A. Touijer, Robert J. Karnes, Niccolo Passoni, et al. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. Eur Urol 2018;73:890-6.
    Touijer K
    Eur Urol; 2018 Jul; 74(1):e18-e19. PubMed ID: 29691082
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036. Methodological Issues.
    Trock BJ; Karnes RJ
    Eur Urol; 2017 Dec; 72(6):e158-e159. PubMed ID: 28576503
    [No Abstract]   [Full Text] [Related]  

  • 8. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
    Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
    J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological outcome for Chinese patients with low-risk prostate cancer eligible for active surveillance and undergoing radical prostatectomy: comparison of six different active surveillance protocols.
    Tsang CF; Tsu JH; Lai TC; Wong KW; Ho BS; Ng AT; Ma WK; Yiu MK
    Hong Kong Med J; 2017 Dec; 23(6):609-15. PubMed ID: 29026057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of pathologically favorable disease in intermediate-risk prostate cancer patients: Implications for active surveillance candidates selection.
    Gandaglia G; Schiffmann J; Schlomm T; Fossati N; Moschini M; Suardi N; Chun FK; Montorsi F; Graefen M; Briganti A
    Prostate; 2015 Sep; 75(13):1484-91. PubMed ID: 26177942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. Eur Urol 2017;71:907-12.
    Fankhauser CD; Mucci LA; Gerke TA
    Eur Urol; 2017 Jul; 72(1):e9-e10. PubMed ID: 28108146
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Amar U. Kishan, Talha Shaikh, Pin-Chieh Wang, et al. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol 2017;71:766-73.
    Van den Broeck T; Karnes RJ; Joniau S
    Eur Urol; 2017 Nov; 72(5):e121-e122. PubMed ID: 28108149
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Jeffrey J. Tosoian, Mufaddal Mamawala, Jonathan I. Epstein, et al. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. Eur Urol 2020;77:675-82.
    Mai Z; Yuan R
    Eur Urol; 2020 Sep; 78(3):e133-e134. PubMed ID: 32444263
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Jeffrey J. Tosoian, Mufaddal Mamawala, Jonathon I. Epstein, et al. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.017.
    Froehner M; Koch R; Thomas C
    Eur Urol; 2020 Aug; 78(2):e91. PubMed ID: 32381458
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Karim A. Touijer, Robert Jeffery Karnes, Niccolo Passoni, et al. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. Eur Urol 2018;73:890-6.
    van Leeuwen PJ; van der Poel HG
    Eur Urol; 2018 Jul; 74(1):e15-e17. PubMed ID: 29661485
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of predictors of unfavorable pathological features in men eligible for active surveillance using radical prostatectomy specimens: a multi-institutional study.
    Mizuno K; Inoue T; Kinoshita H; Yano T; Kawanishi H; Kanda H; Terada N; Kobayashi T; Kamba T; Mikami Y; Shiraishi T; Uemura Y; Imai Y; Honjo G; Shirase T; Okumura K; Kawakita M; Ogura K; Sugimura Y; Matsuda T; Ogawa O
    Jpn J Clin Oncol; 2016 Dec; 46(12):1156-1161. PubMed ID: 27744325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Favorable Gleason 3 + 4 Prostate Cancer Shows Comparable Outcomes With Gleason 3 + 3 Prostate Cancer: Implications for the Expansion of Selection Criteria for Active Surveillance.
    Lee H; Lee IJ; Byun SS; Lee SE; Hong SK
    Clin Genitourin Cancer; 2017 Dec; 15(6):e1117-e1122. PubMed ID: 28843377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Jeffrey J. Tosoian, Debasish Sundi, Bruce J. Trock, et al. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. Eur Urol 2016;69:576-81.
    Yan W; Zhou Z; Li H
    Eur Urol; 2017 Jan; 71(1):e12. PubMed ID: 27262630
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Meelan Bul, Xiaoye Zhu, Antti Rannikko, et al. Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.02.002.
    Ates F; Akyol I; Soydan H
    Eur Urol; 2012 Jul; 62(1):e9; author reply e10-1. PubMed ID: 22512903
    [No Abstract]   [Full Text] [Related]  

  • 20. Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence.
    Corcoran NM; Hong MK; Casey RG; Hurtado-Coll A; Peters J; Harewood L; Goldenberg SL; Hovens CM; Costello AJ; Gleave ME
    BJU Int; 2011 Oct; 108(8 Pt 2):E202-10. PubMed ID: 21443656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.